Transdermal semaglutide administration in mice: Reduces body weight by suppressing appetite and enhancing metabolic rate
45 Exclusion criteria included any contraindication to MRI, history of epilepsy, stroke, brain surgery, or structural brain disease, pregnancy, history of sulfur sensitivity, ongoing asthma or drug dependence, ongoing chronic diseases, history of mental illness, or acute infection during the prior 30 days
References Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al
GHK-Cu improves scalp blood flow through angiogenesis, the formation of new capillaries
Efficacy and safety of co-administered once-weekly cagrilintide 24 mg with once-weekly semaglutide 24 mg in type 2 diabetes. Lancet 402(10403):720730
It is important to mention that the technician in charge of conducting the behavioral tests did not know the animals experimental groups